The therapeutic effect of medlar polysaccharide on blood fat metabolism of rats with nonalcoholic fatty liver disease

Abstract

Objective To explore the effect of medlar polysaccharide(MP) on blood fat metabolism of rat with nonalcoholic fatty liver disease(NAFLD). Methods 40 SD rats were randomly divided into a blank control group(n=7), and a NAFLD model group (n=33). The control group was treated with normal forage, and the control group was treated with high-fat forage. After 8 weeks, 30 NAFLD models were successfully established and divided into three groups randomly: a LBP intervention group (treatment group, n=10) was perfused with 60 mg/(kg•d)MP, a simvastatin intervention group(control group, n=10) was perfused with 5mg/(kg•d) simvastatin, and a model group(model group, n=10) was perfused with the same volume of water along with high fat diet at the same time. After 8 weeks, triglycerides, total cholesterol, ALT, AST, leptin, and adiponectin in the plasma in rat were test. Malondialdehyde, Superoxide Dismutase and Gamma glutamyl cysteinyl glycine were also detected in the liver tissue. Results After 8 weeks, the contents of TG (0.94 ± 0.09 mmol/L vs.1.19 ± 0.13 mmol/L), TC (2.15 ± 0.20 mmol/L vs. 3.52 ± 0.29 mmol/L), ALT (41.75 ± 4.14 U/L vs. 55.34 ± 5.38 U/L), AST (129.61 ± 12.07 U/L vs. 164.96 ± 15.49 U/L), LP (235.69 ± 23.52 pg/ml vs. 284.01 ± 29.43 pg/ml) were decreased, the contents of ADP (35.47 ± 3.09 µg/L vs. 26.31 ± 2.58 µg/L) was increased in serum of the treatment group compared with the model group (P<0.05 or P<0.01)；the contents of SOD (92.40 ± 8.89 U/mg vs. 61.60 ± 5.89 U/mg), GSH (22.25 ± 2.21 mg/g vs. 15.50 ± 1.36 mg/g)were increased, and the contents of MDA (0.84 ± 0.08 nmol/mg vs. 1.07 ± 0.09 nmol/mg) was decreased in liver tissue of the treatment group compared with the model group (P<0.05 or P<0.01). HE stain showed that the treatment group improved the injury. Conclusions Medlar polysaccharide(MP) can inhibit lipid peroxidation by adjusting lipid metabolism. Key words: Nonalcoholic fatty liver disease; Medlar polysaccharidel superoxidase dismutase; Malondialdehyde; Adiponectin; Leptin